#AACR26 | Elena Garralda, Andrea García Garijo, Íñigo González-Larreategui y Daniel Capitán-Leo presentaron diversos estudios y pósteres sobre inmunoterapia y medicina de precisión en el @AACR, uno de los congresos líderes en investigación del cáncer.
➡️ https://t.co/DMxRCHhk7m
#UITM
We are proud to announce that our PhD student, @dcapi14, presented yesterday a poster at #EACR2025 in Lisbon titled “MYC targeting by Omomyc boosts efficacy and overcomes resistance to KRAS inhibitors”. Well done, Dani! @VHIO@EACRnews#cancer
👏 Enhorabona @dcapi14 i Cristina Molina ‼️
Dos investigadors del VHIO han estat guardonats amb beques #INPhINIT@FundlaCaixa per dur a terme el seu doctorat i avançar en la recerca en càncer 👉 https://t.co/RimQlwFVX4
🔴 El fàrmac OMO-103, desenvolupat per @peptomyc, es provarà com a teràpia per a pacients amb osteosarcoma avançat.
🔬 L'assaig està finançat per l'@OSInstitute i té com a objectius avaluar l'activitat clínica, la seguretat i la farmacodinàmica ➡️ https://t.co/mnARCBAVtq
#OSTEOMYC
Today our @ignigor presented at the XVIII congress of the Catalan Society of Immunology talking about the therapeutic impact and reactivation of tumor immunity by MYC inhibition in KRAS-driven NSCLC with diverse mutational landscapes. 👏 @VHIO@peptomyc
@dcapi14 is presenting today a poster titled “Myc targeting by Omomyc enhances the efficacy and overcomes resistance to the KRAS inhibitor sotorasib in NSCLC” at #ASEICAcongress. 👏 @VHIO@peptomyc
@SilviaCasacub is representing @Peptomyc and the @LSoucekLab (at @VHIO) at #ASEICACongress with a talk and poster about how MYC inhibition reprograms tumor immunity and enhances immunotherapy efficacy in KRASmut NSCLC. 👏
I am thrilled to share that I have been awarded the prestigious "La Caixa" Foundation INPhINIT Retaning Fellowship @BecarisFLC , which will suport my PhD Studies at @VHIO over the next four years. Very grateful to @LauraSoucek, @SilviaCasacub, @ignigor and the whole @LSoucekLab!
I am happy to share our review in Signal Transduction and Targeted Therapy (@Nature) on #RAS and #MYC cooperation, co-authored by @SilviaCasacub, @ignigor, and @dcapi14. RAS and MYC are two of the most commonly altered oncogenes in cancer. https://t.co/7lD3HkNN1k
Our review in Signal Transduction and Targeted Therapy (@Nature) on #RAS and #MYC cooperation, co-authored by @SilviaCasacub, @ignigor, @dcapi14 and @LauraSoucek is out. RAS and MYC are two of the most commonly altered oncogenes in cancer. https://t.co/Uq44kUt9Pw
🔬 Los resultados del primer ensayo clínico de #Omomyc en humanos han llevado a la puesta en marcha de un segundo ensayo clínico fase Ib en pacientes con cáncer de páncreas metastásico.
➡️ https://t.co/sAr1QZmNZu
#AGAUR#NextGeneration | @LauraSoucek @ElenaGarralda